Sunday, 19 August 2012

Exparel





Dosage Form: injection, suspension, liposomal
FULL PRESCRIBING INFORMATION

1. INDICATIONS AND USAGE


Exparel is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia.


Exparel has not been studied for use in patients younger than 18 years of age.



2. DOSAGE AND ADMINISTRATION


Exparel is intended for single-dose administration only. The recommended dose of Exparel is based on the surgical site and the volume required to cover the area.













1Infiltrate 7 mL of Exparel into the tissues surrounding the osteotomy and 1 mL into the subcutaneous tissue.
2Dilute 20 mL of Exparel with 10 mL of saline, for a total of 30 mL, and divide the mixture into six 5 mL aliquots. Perform the anal block by visualizing the anal sphincter as a clock face and slowly infiltrating one aliquot to each of the even numbers.
SurgeryDose of ExparelVolume of Exparel
Bunionectomy1106 mg8 mL
Hemorrhoidectomy2266 mg20 mL

Injection Instructions


Exparel should be injected slowly into soft tissues of the surgical site with frequent aspiration to check for blood and minimize the risk of intravascular injection.


  • Exparel is intended for single-dose infiltration only.

  • Exparel should be administered with a 25 gauge or larger bore needle.

  • The maximum dosage of Exparel should not exceed 266 mg (20 mL, 1.3% of undiluted drug).

  • Do not administer Exparel if the product is discolored.

  • Do not administer Exparel if it is suspected that the vial has been frozen as reflected by the temperature indicator or exposed to high temperature (greater than 40°C or 104°F) for an extended period.

  • Exparel can be administered undiluted or diluted up to 0.89 mg/mL (i.e. 1:14 dilution by volume) with preservative-free normal (0.9%) sterile saline for injection.

  • Vials of Exparel should be inverted multiple times to re-suspend the particles immediately prior to withdrawal from the vial.

  • Diluted suspensions of Exparel should be used within 4 hours of preparation in a syringe.


Administration Precautions


Some physicochemical incompatibilities exist between Exparel and certain other drugs. Direct contact of Exparel with these drugs results in a rapid increase in free (unencapsulated) bupivacaine, altering Exparel characteristics and potentially affecting the safety and efficacy of Exparel. Therefore, admixing Exparel with other drugs prior to administration is not recommended [See Drug Interactions (7)].


  • Non-bupivacaine based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from Exparel if administered together locally. The administration of Exparel may follow the administration of lidocaine after a delay of 20 minutes or more.

  • Bupivacaine HCl, when injected immediately before Exparel, may impact the pharmacokinetic and/or physicochemical properties of the drugs when the milligram dose of bupivacaine HCl solution exceeds 50% of the Exparel dose. Exparel contains bupivacaine; therefore, coadministration of both drugs will increase the overall exposure to bupivacaine.

  • When a topical antiseptic such as povidone iodine (e.g., Betadine®) is applied, the site should be allowed to dry before Exparel is administered into the surgical site. Exparel should not be allowed to come into contact with antiseptics such as povidone iodine in solution.

Studies conducted with Exparel demonstrated that the most common implantable materials (polypropylene, PTFE, silicone, stainless steel, and titanium) are not affected by the presence of Exparel any more than they are by saline. None of the materials studied had an adverse effect on Exparel.


When administered in recommended doses and concentrations, bupivacaine HCl does not ordinarily produce irritation or tissue damage and does not cause methemoglobinemia.



Non-Interchangeability with Other Formulations of Bupivacaine


Different formulations of bupivacaine are not bioequivalent even if the milligram dosage is the same. Therefore, it is not possible to convert dosing from any other formulations of bupivacaine to Exparel and vice versa.


Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug's functional properties relative to those of the unencapsulated or nonlipid-associated drug. In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component. Such differences may affect functional properties of these drug products. Do not substitute.



Dosing in Special Populations


Exparel has not been studied in patients younger than 18 years of age, pregnant patients or patients who are nursing.



3. DOSAGE FORMS AND STRENGTHS


Exparel (bupivacaine liposome injectable suspension)


  • 10 mL single use vial, 1.3% (13.3 mg/mL)

  • 20 mL single use vial, 1.3% (13.3 mg/mL)


4. CONTRAINDICATIONS


Exparel is contraindicated in obstetrical paracervical block anesthesia. While Exparel has not been tested with this technique, the use of bupivacaine HCl with this technique has resulted in fetal bradycardia and death.



5. WARNINGS AND PRECAUTIONS



Warnings and Precautions for Bupivacaine containing Products


The safety and effectiveness of bupivacaine and other amide-containing products depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. As there is a potential risk of severe life-threatening adverse effects associated with the administration of bupivacaine, any bupivacaine-containing product should be administered in a setting where trained personnel and equipment are available to promptly treat patients who show evidence of neurological or cardiac toxicity [See Overdosage (10)].


Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after injection of bupivacaine and other amide-containing products. Restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, depression, or drowsiness may be early warning signs of central nervous system toxicity.


Bupivacaine and other amide-containing products should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.


Injection of multiple doses of bupivacaine and other amide-containing products may cause significant increases in plasma concentrations with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood concentrations varies with the status of the patient.


Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.


Central Nervous System Reactions


The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug. Neurologic effects following infiltration of soft tissue may include persistent anesthesia, paresthesias, weakness, and paralysis, all of which may have slow, incomplete, or no recovery.


Central nervous system reactions are characterized by excitation and/or depression. Restlessness, anxiety, dizziness, tinnitus, blurred vision, or tremors may occur, possibly proceeding to convulsions. However, excitement may be transient or absent, with depression being the first manifestation of an adverse reaction. This may quickly be followed by drowsiness merging into unconsciousness and respiratory arrest. Other central nervous system effects may be nausea, vomiting, chills, and constriction of the pupils. The incidence of convulsions associated with the use of local anesthetics varies with the procedure used and the total dose administered.


Cardiovascular System Reactions


Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure [See Warnings and Precautions (5.1) and Overdosage (10)].


Allergic Reactions


Allergic-type reactions are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients. These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly anaphylactoid-like symptoms (including severe hypotension). Cross-sensitivity among members of the amide-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitively established.


Chondrolysis


Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been postmarketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humerol chondrolysis have been described in pediatric patients and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness, and loss of motion can be variable, but may begin as early as the second month after surgery. Currently, there is no effective treatment for chondrolysis; patients who have experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.



Warnings and Precautions Specific for Exparel


As there is a potential risk of severe life-threatening adverse effects associated with the administration of bupivacaine, Exparel should be administered in a setting where trained personnel and equipment are available to promptly treat patients who show evidence of neurological or cardiac toxicity [See Overdosage (10)].


Caution should be taken to avoid accidental intravascular injection of Exparel. Convulsions and cardiac arrest have occurred following accidental intravascular injection of bupivacaine and other amide-containing products.


Using Exparel followed by other bupivacaine formulations has not been studied in clinical trials. Other formulations of bupivacaine should not be administered within 96 hours following administration of Exparel [See Clinical Pharmacology (12.3)].


Exparel has not been evaluated for the following uses and, therefore, is not recommended for these types of analgesia or routes of administration.


  • epidural

  • intrathecal

  • regional nerve blocks

  • intravascular or intra-articular use

Exparel has not been evaluated for use in the following patient population and, therefore, it is not recommended for administration to these groups.


  • patients younger than 18 years old

  • pregnant patients

  • nursing patients

The ability of Exparel to achieve effective anesthesia has not been studied. Therefore, Exparel is not indicated for pre-incisional or pre-procedural loco-regional anesthetic techniques that require deep and complete sensory block in the area of administration.



6. ADVERSE REACTIONS



General


The most commonly encountered acute adverse experiences to bupivacaine and all amide-type local anesthetics that demand immediate counter-measures are related to the central nervous and cardiovascular systems.


High plasma concentrations of bupivacaine can occur from overdosage, unintended intravascular injection, or accumulation of bupivacaine in plasma secondary to decreased hepatic metabolic degradation of the drug or diminished plasma protein binding capacity due to acidosis, pathologically lowered plasma protein production, or competition with other drugs for protein binding sites. Although rare, some individuals have a lower tolerance to and are supersensitive to bupivacaine and other amide-type local anesthetics and may rapidly develop signs of toxicity at low doses [See Overdosage (10)].



Adverse Reactions Reported in All Wound Infiltration Clinical Studies


Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.


The safety of Exparel was evaluated in 10 randomized, double-blind, local administration into the surgical site clinical studies involving 823 patients undergoing various surgical procedures. Patients were administered a dose ranging from 66 to 532 mg of Exparel. In these studies, the most common adverse reactions (incidence greater than or equal to 10%) following Exparel administration were nausea, constipation, and vomiting.


The common adverse reactions (incidence greater than or equal to 2% to less than 10%) following Exparel administration were pyrexia, dizziness, edema peripheral, anemia, hypotension, pruritus, tachycardia, headache, insomnia, anemia postoperative, muscle spasms, hemorrhagic anemia, back pain, somnolence, and procedural pain.


The less common/rare adverse reactions (incidence less than 2%) following Exparel administration were chills, erythema, bradycardia, anxiety, urinary retention, pain, edema, tremor, dizziness postural, paresthesia, syncope, incision site edema, procedural hypertension, procedural hypotension, procedural nausea, muscular weakness, neck pain, pruritus generalized, rash pruritic, hyperhidrosis, cold sweat, urticaria, bradycardia, palpitations, sinus bradycardia, supraventricular extrasystoles, ventricular extrasystoles, ventricular tachycardia, hypertension, pallor, anxiety, confusional state, depression, agitation, restlessness, hypoxia, laryngospasm, apnea, respiratory depression, respiratory failure, body temperature increased, blood pressure increased, blood pressure decreased, oxygen saturation decreased, urinary retention, urinary incontinence, vision blurred, tinnitus, drug hypersensitivity, and hypersensitivity.


Neurological and Cardiac Adverse Reactions Reported in All Wound Infiltration Clinical Studies


In the Exparel wound infiltration studies, adverse reactions with an incidence greater than or equal to 1% in the Nervous System Disorders system organ class following Exparel administration were dizziness (6.2%), headache (3.8%), somnolence (2.1%), hypoesthesia (1.5%), and lethargy (1.3%). The adverse reactions with an incidence greater than or equal to 1% in the Cardiac Disorders system organ class following Exparel administration were tachycardia (3.9%) and bradycardia (1.6%).


Adverse Reactions Reported in Placebo-Controlled Wound Infiltration Clinical Studies


Adverse reactions with an incidence greater than or equal to 2% reported by patients in clinical studies comparing 8 mL Exparel 1.3% (106 mg) to placebo and 20 mL Exparel 1.3% (266 mg) to placebo are shown in Table 1.


















































































































































































Table 1: Treatment-Emergent Adverse Reactions (TEAE) with an Incidence Greater than or Equal to 2%: Placebo Controlled Studies
a Study 1: Bunionectomy
b Study 2: Hemorrhoidectomy
At each level of summation (overall, system organ class, preferred term), patients are only counted once.

Preferred terms are included where at least 2% of patients reported the event in any treatment group.

TEAE = treatment-emergent adverse event.
STUDY 1aSTUDY 2b
ExparelPlaceboExparelPlacebo
System Organ Class

     Preferred Term
8 mL/1.3% (106 mg)

(N=97)

n (%)
(N=96)

n (%)
20 mL/1.3% (266 mg)

(N=95)

n (%)
(N=94)

n (%)
 
Any TEAE53 (54.6)59 (61.5)10 (10.5)17 (18.1)
 
Gastrointestinal Disorders41 (42.3)38 (39.6)7 (7.4)13 (13.8)
     Nausea39 (40.2)36 (37.5)2 (2.1)1 (1.1)
     Vomiting27 (27.8)17 (17.7)2 (2.1)4 (4.3)
     Constipation2 (2.1)1 (1.0)2 (2.1)2 (2.1)
     Anal Hemorrhage0 (0.0)0 (0.0)3 (3.2)4 (4.3)
     Painful Defecation0 (0.0)0 (0.0)2 (2.1)5 (5.3)
     Rectal Discharge0 (0.0)0 (0.0)1 (1.1)3 (3.2)
 
Nervous System Disorders20 (20.6)30 (31.3)0 (0.0)0 (0.0)
     Dizziness11 (11.3)25 (26.0)0 (0.0)0 (0.0)
     Headache5 (5.2)8 (8.3)0 (0.0)0 (0.0)
     Somnolence5 (5.2)1 (1.0)0 (0.0)0 (0.0)
     Syncope2 (2.1)0 (0.0)0 (0.0)0 (0.0)
 
Skin And Subcutaneous Tissue Disorders8 (8.2)7 (7.3)0 (0.0)0 (0.0)
     Pruritus Generalized5 (5.2)6 (6.3)0 (0.0)0 (0.0)
     Pruritus3 (3.1)1 (1.0)0 (0.0)0 (0.0)
 
Investigations5 (5.2)3 (3.1)4 (4.2)3 (3.2)
     Alanine Aminotransferase Increased3 (3.1)3 (3.1)1 (1.1)0 (0.0)
     Aspartate Aminotransferase Increased3 (3.1)2 (2.1)0 (0.0)0 (0.0)
     Blood Creatinine Increased2 (2.1)0 (0.0)0 (0.0)0 (0.0)
     Body Temperature Increased0 (0.0)0 (0.0)3 (3.2)3 (3.2)
 
General Disorders And Administration Site Conditions4 (4.1)0 (0.0)1 (1.1)1 (1.1)
     Feeling Hot2 (2.1)0 (0.0)0 (0.0)0 (0.0)
     Pyrexia2 (2.1)0 (0.0)1 (1.1)1 (1.1)
 
Infections And Infestations2 (2.1)1 (1.0)0 (0.0)0 (0.0)
     Fungal Infection2 (2.1)1 (1.0)0 (0.0)0 (0.0)
 
Injury, Poisoning And Procedural Complications2 (2.1)0 (0.0)0 (0.0)0 (0.0)
     Post Procedural Swelling2 (2.1)0 (0.0)0 (0.0)0 (0.0)
 
Metabolism And Nutrition Disorders2 (2.1)2 (2.1)0 (0.0)0 (0.0)
     Decreased Appetite2 (2.1)2 (2.1)0 (0.0)0 (0.0)

Drug Interactions


Exparel can be administered undiluted or diluted up to 0.89 mg/mL (i.e., 1:14 dilution by volume) with preservative-free normal (0.9%) sterile saline for injection. Exparel must not be diluted with water or other hypotonic agents as it will result in disruption of the liposomal particles.


Exparel should not be admixed with lidocaine or other non-bupivacaine-based local anesthetics.


Exparel may be locally administered after at least 20 minutes following local administration of lidocaine.


Exparel should not be admixed with other drugs prior to administration.



8. USE IN SPECIFIC POPULATIONS



Pregnancy


Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women of the effect of bupivacaine on the developing fetus. Exparel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Bupivacaine hydrochloride (HCl) produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses. This does not exclude the use of Exparel at term for analgesia [See Labor and Delivery (8.2)].


Bupivacaine HCl was administered subcutaneously to rats and rabbits during the period of fetal organogenesis. No embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality. An increase in embryo-fetal deaths was observed in rabbits at the high dose in the absence of maternal toxicity.


Administration of bupivacaine HCl to rats during pregnancy and lactation resulted in decreased offspring survival.



Labor and Delivery


Bupivacaine hydrochloride is contraindicated for obstetrical paracervical block anesthesia.


Local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity [See Clinical Pharmacology (12.3)]. The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function.



Nursing mothers


Bupivacaine has been reported to be excreted to some extent in human milk, suggesting that the nursing infant could be theoretically exposed to a dose of the drug. Because of the potential for serious adverse reactions in nursing infants from bupivacaine, a decision should be made whether to discontinue nursing or not administer Exparel, taking into account the importance of the drug to the mother.



Pediatric use


Safety and effectiveness in pediatric patients below the age of 18 have not been established.



Geriatric use


Of the total number of patients in the Exparel wound infiltration clinical studies (N=823), 171 patients were greater than or equal to 65 years of age and 47 patients were greater than or equal to 75 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients. Clinical experience with Exparel has not identified differences in efficacy or safety between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.


In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients. Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to bupivacaine may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection of Exparel.



Hepatic Impairment


Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.



Renal Impairment


Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Care should be taken in dose selection of Exparel.



10. OVERDOSAGE


Acute emergencies from local anesthetics are generally related to high plasma concentrations encountered during therapeutic use of local anesthetics or to unintended intravascular injection of local anesthetic solution [See Warnings and Precautions (5) and Adverse Reactions (6)].


In the clinical study program, maximum plasma concentration (Cmax) values of approximately 34,000 ng/mL were reported and likely reflected inadvertent intravascular administration of Exparel or systemic absorption of Exparel at the surgical site. The plasma bupivacaine measurements did not discern between free and liposomal-bound bupivacaine making the clinical relevance of the reported values uncertain; however, no discernable adverse events or clinical sequelae were observed in these patients.



11. DESCRIPTION


Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel into soft tissue, bupivacaine is released from the multivesicular liposomes over a period of time.



Active Ingredient


Bupivacaine is related chemically and pharmacologically to the amide-type local anesthetics. It is a homologue of mepivacaine and is related chemically to lidocaine. All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino, or piperidine group. They differ in this respect from the procaine-type local anesthetics, which have an ester linkage. Chemically, bupivacaine is 1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide with a molecular weight of 288.4. Bupivacaine has the following structural formula:



Bupivacaine is present in Exparel at a concentration of 13.3 mg/mL.



Lipid Formulation


The median diameter of the liposome particles ranges from 24 to 31 µm. The liposomes are suspended in a 0.9% sodium chloride solution. Each vial contains bupivacaine at a nominal concentration of 13.3 mg/mL. Inactive ingredients and their nominal concentrations are: cholesterol, 4.7 mg/mL; 1, 2-dipalmitoyl-sn-glycero-3 phospho-rac-(1-glycerol) (DPPG), 0.9 mg/mL; tricaprylin, 2.0 mg/mL; and 1, 2-dierucoylphosphatidylcholine (DEPC), 8.2 mg/mL. The pH of Exparel is in the range of 5.8 to 7.4.


Liposomal encapsulation or incorporation in a lipid complex can substantially affect a drug's functional properties relative to those of the unencapsulated or nonlipid-associated drug. In addition, different liposomal or lipid-complexed products with a common active ingredient may vary from one another in the chemical composition and physical form of the lipid component. Such differences may affect functional properties of these drug products. Do not substitute.



12. CLINICAL PHARMACOLOGY



Mechanism of action


Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.



Pharmacodynamics


Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conductivity and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Clinical reports and animal research suggest that these cardiovascular changes are more likely to occur after accidental intravascular injection of bupivacaine.


Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression, or both. Apparent central stimulation is manifested as restlessness, tremors, and shivering progressing to convulsions, followed by depression and coma progressing ultimately to respiratory arrest. However, the local anesthetics have a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited state.



Pharmacokinetics


Local infiltration of Exparel results in significant systemic plasma levels of bupivacaine which can persist for 96 hours [See Warnings and Precautions (5.2)]. Systemic plasma levels of bupivacaine following administration of Exparel are not correlated with local efficacy.


Absorption


The rate of systemic absorption of bupivacaine is dependent upon the total dose of drug administered, the route of administration, and the vascularity of the administration site.


Pharmacokinetic parameters of Exparel after local administration were evaluated following surgical procedures. Descriptive statistics of pharmacokinetic parameters of representative Exparel doses in each study are provided in Table 2.



























Table 2: Summary of Pharmacokinetic Parameters for Bupivacaine after Administration of Single Doses of Exparel
Note: Arithmetic mean (standard deviation) except Tmax (median).
Exparel
Bunionectomy

106 mg (8 mL)
Hemorrhoidectomy

266 mg (20 mL)
 
(N=26)(N=25) 
Cmax (ng/mL)166 (92.7)867 (353)
Tmax (h)20.5
AUC(0-t) (h×ng/mL)5864 (2038)16,867 (7868)
AUC(inf) (h×ng/mL)7105 (2283)18,289 (7569)
t½ (h)34.1 (17.0)23.8 (39.4)

Distribution


After bupivacaine has been released from Exparel and is absorbed systemically, bupivacaine distribution is expected to be the same as for any bupivacaine HCl solution formulation.


Local anesthetics including bupivacaine are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.


Local anesthetics including bupivacaine appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by (1) the degree of plasma protein binding, (2) the degree of ionization, and (3) the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4). The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, non-ionized drugs such as bupivacaine readily enter the fetal blood from the maternal circulation.


Metabolism


Amide-type local anesthetics, such as bupivacaine, are metabolized primarily in the liver via conjugation with glucuronic acid. Pipecolylxylidine (PPX) is the major metabolite of bupivacaine; approximately 5% of bupivacaine is converted to PPX. Elimination of drug depends largely upon the availability of plasma protein binding sites in the circulation to carry it to the liver where it is metabolized.


Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic disease. Patients with hepatic disease, especially those with severe hepatic disease, may be more susceptible to the potential toxicities of the amide-type local anesthetics.


Excretion


After bupivacaine has been released from Exparel and is absorbed systemically, bupivacaine excretion is expected to be the same as for other bupivacaine formulations.


The kidney is the main excretory organ for most local anesthetics and their metabolites. Only 6% of bupivacaine is excreted unchanged in the urine.


Urinary excretion is affected by urinary perfusion and factors affecting urinary pH. Acidifying the urine hastens the renal elimination of local anesthetics. Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of renal disease, factors affecting urinary pH, and renal blood flow.


Specific Populations


Hepatic Impairment


The effects of decreased hepatic function on bupivacaine pharmacokinetics following administration of Exparel were studied in patients with moderate hepatic impairment. Consistent with the hepatic clearance of bupivacaine, mean plasma concentrations were higher in patients with moderate hepatic impairment than in the healthy control volunteers with approximately 1.5- and 1.6-fold increases in the mean values for Cmax and the area under the curve (AUC), respectively.


Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, these drugs should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations [See Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].


Renal Impairment


Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Care should be taken in dose selection of Exparel [See Use in Specific Populations (8.7)].


Age


Various pharmacokinetic parameters of the local anesthetics such as bupivacaine can be significantly altered by the age of the patient.


In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients.


Bupivacaine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection of Exparel [See Use in Specific Populations (8.5)].



13. NONCLINICAL TOXICOLOGY



Carcinogenesis, mutagenesis, impairment of fertility


Long-term studies in animals of most local anesthetics, including bupivacaine, to evaluate the carcinogenic potential have not been conducted. Mutagenic potential and the effect on fertility have not been determined. There is no evidence from human data that bupivacaine may be carcinogenic or mutagenic or that it impairs fertility.



14. CLINICAL STUDIES


The efficacy of Exparel was compared to placebo in two multicenter, randomized, double-blinded clinical trials. One trial evaluated the treatments in patients undergoing bunionectomy; the other trial evaluated the treatments in patients undergoing hemorrhoidectomy. Exparel has not been demonstrated to be safe and effective in other procedures.



Bunionectomy


A multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluated the safety and efficacy of 106 mg Exparel in 193 patients undergoing bunionectomy. The mean age was 43 years (range 18 to 72). Study medication was administered directly into the wound at the conclusion of the surgery, prior to wound closure. Pain intensity was rated by the patients on a 0 to 10 numeric rating scale (NRS) out to 72 hours. Postoperatively, patients were allowed rescue medication (5 mg oxycodone/325 mg acetaminophen orally every 4 to 6 hours as needed) or, if that was insufficient within the first 24 hours, ketorolac (15 to 30 mg IV). The primary outcome measure was the area under the curve (AUC) of the NRS pain intensity scores (cumulative pain scores) collected over the first 24 hour period. There was a significant treatment effect for Exparel compared to placebo.


In this clinical study, Exparel demonstrated a significant reduction in pain intensity compared to placebo for up to 24 hours. The difference in mean pain intensity between treatment groups occurred only during the first 24 hours following study drug administration. Between 24 and 72 hours after study drug administration, there was minimal to no difference between Exparel and placebo treatments on mean pain intensity.



Hemorrhoidectomy


A multicenter, random

Saturday, 18 August 2012

Ciproxin Tablets 500mg




Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes.


If you have any doubts or queries about your medication, please contact your doctor or pharmacist.





Ciproxin 500 mg film-coated tablets


Ciprofloxacin



Read all of this leaflet carefully before you start taking this medicine.


  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



In this leaflet:


  • 1. What Ciproxin is and what it is used for

  • 2. Before you take Ciproxin

  • 3. How to take Ciproxin

  • 4. Possible side effects

  • 5. How to store Ciproxin

  • 6. Further information




What Ciproxin Is And What It Is Used For


Ciproxin is an antibiotic belonging to the fluoroquinolone family. The active substance is ciprofloxacin. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria.




Adults


Ciproxin is used in adults to treat the following bacterial infections:


  • respiratory tract infections

  • long lasting or recurring ear or sinus infections

  • urinary tract infections

  • infections of the testicles

  • genital organ infections in women

  • gastro-intestinal tract infections and intra-abdominal infections

  • skin and soft tissue infections

  • bone and joint infections

  • to treat infections in patients with a very low white blood cell count (neutropenia)

  • to prevent infections in patients with a very low white blood cell count (neutropenia)

  • to prevent infections due to the bacterium Neisseria meningitidis

  • anthrax inhalation exposure

If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to Ciproxin.




Children and adolescents


Ciproxin is used in children and adolescents, under specialist medical supervision, to treat the following bacterial infections:


  • lung and bronchial infections in children and adolescents suffering from cystic fibrosis

  • complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis)

  • anthrax inhalation exposure

Ciproxin may also be used to treat other specific severe infections in children and adolescents when your doctor considered this necessary.




Before You Take Ciproxin



Do not take Ciproxin if you are:


  • allergic (hypersensitive) to the active substance, to other quinolone drugs or to any of the other ingredients of Ciproxin (see section 6)

  • taking tizanidine (see Section 2: Taking other medicines)



Take special care with Ciproxin



Before taking Ciproxin


Tell your doctor if you:


  • have ever had kidney problems because your treatment may need to be adjusted

  • suffer from epilepsy or other neurological conditions

  • have a history of tendon problems during previous treatment with antibiotics such as Ciproxin

  • have myasthenia gravis (a type of muscle weakness)

  • have a history of abnormal heart rhythms (arrythmias)


While taking Ciproxin


Tell your doctor immediately, if any of the following occurs while taking Ciproxin. Your doctor will decide whether treatment with Ciproxin needs to be stopped.



  • Severe, sudden allergic reaction (an anaphylactic reaction/shock, angio-oedema). Even with the first dose, there is a small chance that you may experience a severe allergic reaction with the following symptoms: tightness in the chest, feeling dizzy, sick or faint, or experiencing dizziness when standing up. If this happens, stop taking Ciproxin and contact your doctor immediately.


  • Pain and swelling in the joints and tendinitis may occur occasionally, particularly if you are elderly and are also being treated with corticosteroids. At the first sign of any pain or inflammation stop taking Ciproxin and rest the painful area. Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture.

  • If you suffer from epilepsy or other neurological conditions such as cerebral ischemia or stroke, you may experience side effects associated with the central nervous system. If this happens, stop taking Ciproxin and contact your doctor immediately.

  • You may experience psychiatric reactions the first time you take Ciproxin. If you suffer from depression or psychosis, your symptoms may become worse under treatment with Ciproxin. If this happens, stop taking Ciproxin and contact your doctor immediately.

  • You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or weakness. If this happens, stop taking Ciproxin and contact your doctor immediately.


  • Diarrhoea may develop while you are taking antibiotics, including Ciproxin, or even several weeks after you have stopped taking them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, stop taking Ciproxin immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements and contact your doctor.

  • Tell the doctor or laboratory staff that you are taking Ciproxin if you have to provide a blood or urine sample.

  • Ciproxin may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, stop taking Ciproxin and contact your doctor immediately.

  • Ciproxin may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.

  • Tell your doctor if you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase (G6PD), since you may experience a risk of anemia with ciprofloxacin.

  • Your skin becomes more sensitive to sunlight or ultraviolet (UV) light when taking Ciproxin. Avoid exposure to strong sunlight, or artificial UV light such as sunbeds.



Taking other medicines


Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including any that you obtained without a prescription.



Do not take Ciproxin together with tizanidine, because this may cause side effects such as low blood pressure and sleepiness (see Section 2: "Do not take Ciproxin").


The following medicines are known to interact with Ciproxin in your body. Taking Ciproxin together with these medicines can influence the therapeutic effect of those medicines. It can also increase the probability of experiencing side effects.



Tell your doctor if you are taking:


  • warfarin or other oral anti-coagulants (to thin the blood)

  • probenecid (for gout)

  • methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis)

  • theophylline (for breathing problems)

  • tizanidine (for muscle spasticity in multiple sclerosis)

  • clozapine (an antipsychotic)

  • ropinirole (for Parkinson’s disease)

  • phenytoin (for epilepsy)

Ciproxin may increase the levels of the following medicines in your blood:


  • pentoxifylline (for circulatory disorders)

  • caffeine

Some medicines reduce the effect of Ciproxin. Tell your doctor if you take or wish to take:


  • antacids

  • mineral supplements

  • sucralfate

  • a polymeric phosphate binder (e.g. sevelamer)

  • medicines or supplements containing calcium, magnesium, aluminium or iron

If these preparations are essential, take Ciproxin about two hours before or no sooner than four hours after them.




Taking Ciproxin with food and drink


Unless you take Ciproxin during meals, do not eat or drink any dairy products (such as milk or yoghurt) or drinks with added calcium when you take the tablets, as they may affect the absorption of the active substance.




Pregnancy and breast-feeding


It is preferable to avoid the use of Ciproxin during pregnancy. Tell your doctor if you are planning to get pregnant.


Do not take Ciproxin during breast feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.




Driving and using machines


Ciproxin may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to Ciproxin before driving a vehicle or operating machinery. If in doubt, talk to your doctor.





How To Take Ciproxin


Your doctor will explain to you exactly how much Ciproxin you will have to take as well as how often and for how long. This will depend on the type of infection you have and how bad it is.


Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.


The treatment usually lasts from 5 to 21 days, but may take longer for severe infections. Take the tablets exactly as your doctor has told you. Ask your doctor or pharmacist if you are not sure how many tablets to take and how to take Ciproxin.


  • a. Swallow the tablets with plenty of fluid. Do not chew the tablets because they do not taste nice.

  • b. Do try to take the tablets at around the same time every day.

  • c. You can take the tablets at mealtimes or between meals. Any calcium you take as part of a meal will not seriously affect uptake. However, do not take Ciproxin tablets with dairy products such as milk or yoghurt or with fortified fruit juices (e.g. calcium-fortified orange juice).

Remember to drink plenty of fluids while you are taking Ciproxin.



If you take more Ciproxin than you should


  • If you take more than the prescribed dose, get medical help immediately. If possible, take your tablets or the box with you to show the doctor.



If you forget to take Ciproxin


  • Take the normal dose as soon as possible and then continue as prescribed. However, if it is almost time for your next dose, do not take the missed dose and continue as usual. Do not take a double dose to make up for a forgotten dose. Be sure to complete your course of treatment.



If you stop taking Ciproxin


  • It is important that you finish the course of treatment even if you begin to feel better after a few days. If you stop taking this medicine too soon, your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also develop resistance to the antibiotic.


If you have any more questions about the use of this product, ask your doctor or pharmacist.




Possible Side Effects


Like all medicines, Ciproxin can cause side effects, although not everybody gets them.


If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.



Common side effects (between 1 and 10 in every 100 people are likely to get these):


  • nausea, diarrhoea

  • joint pains in children


Uncommon side effects (between 1 and 10 in every 1,000 people are likely to get these):


  • fungal superinfections

  • a high concentration of eosinophils, a type of white blood cell

  • loss of appetite (anorexia)

  • hyperactivity or agitation

  • headache, dizziness, sleeping problems, or taste disorders

  • vomiting, abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), or wind

  • increased amounts of certain substances in the blood (transaminases and/or bilirubin)

  • rash, itching, or hives

  • joint pain in adults

  • poor kidney function

  • pains in your muscles and bones, feeling unwell (asthenia), or fever

  • increase in blood alkaline phosphatase (a certain substance in the blood)


Rare side effects (between 1 and 10 in every 10,000 people are likely to get these):


  • inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see Section 2: Take special care with Ciproxin)

  • changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), increased or decreased amounts of a blood clotting factor (thrombocytes)

  • allergic reaction, swelling (oedema), or rapid swelling of the skin and mucous membranes (angio-oedema)

  • increased blood sugar (hyperglycaemia)

  • confusion, disorientation, anxiety reactions, strange dreams, depression, or hallucinations

  • pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors, seizures (see Section 2: Take special care with Ciproxin), or giddiness

  • eyesight problems

  • tinnitus, loss of hearing, impaired hearing

  • rapid heartbeat (tachycardia)

  • expansion of blood vessels (vasodilation), low blood pressure, or fainting

  • shortness of breath, including asthmatic symptoms

  • liver disorders, jaundice (cholestatic icterus), or hepatitis

  • sensitivity to light (see Section 2: Take special care with Ciproxin)

  • muscle pain, inflammation of the joints, increased muscle tone, or cramp

  • kidney failure, blood or crystals in the urine (see Section 2: Take special care with Ciproxin), urinary tract inflammation

  • fluid retention or excessive sweating

  • abnormal levels of a clotting factor (prothrombin) or increased levels of the enzyme amylase


Very rare side effects (less than 1 in every 10,000 people are likely to get these):


  • a special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis ); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section 2: Take special care with Ciproxin)

  • severe allergic reactions (anaphylactic reaction or anaphylactic shock, which can be fatal - serum sickness) (see Section 2: Take special care with Ciproxin)

  • mental disturbances (psychotic reactions) (see Section 2: Take special care with Ciproxin)

  • migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory disorders), pressure on the brain (intracranial pressure)

  • visual colour distortions

  • inflammation of the wall of the blood vessels (vasculitis)

  • pancreatitis

  • death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure

  • small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes (for example, the potentially fatal Stevens-Johnson syndrome or toxic epidermal necrolysis)

  • muscle weakness, tendon inflammation, tendon rupture – especially of the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Take special care with Ciproxin); worsening of the symptoms of myasthenia gravis (see Section 2: Take special care with Ciproxin)


Frequency not known (cannot be estimated from the available data)


  • troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities

  • severe cardiac rhythm abnormalities, irregular heart beat (Torsades de Pointes)



How To Store Ciproxin



Keep out of the reach and sight of children.


Do not use Ciproxin after the expiry date, which is stated on the blister and carton after “EXP”: The expiry date refers to the last day of that month.


This medicinal product does not require any special storage conditions.


Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of any medicines no longer required. These measures will help to protect the environment.




Further Information



What Ciproxin contains


The active substance is ciprofloxacin.


Each film-coated tablet contains 500 mg ciprofloxacin (as hydrochloride).


The other ingredients are:


Tablet core: cellulose microcrystalline, crospovidone, magnesium stearate, maize starch, silica colloidal anhydrous.


Film-coat: hypromellose, macrogol 4000, titanium dioxide (E171).




What Ciproxin looks like and contents of the pack


Ciproxin 500 mg tablets: oblong, nearly white to slightly yellowish film-coated tablets marked with "CIP score 500" on one side and "BAYER" on the other side.


The tablets can be divided into equal halves.


Pack sizes of 6, 8, 10, 12, 14, 16, 20, 28, 50, 100, 160, or 500 film-coated tablets.


Not all pack sizes may be marketed.




Marketing Authorisation Holder and Manufacturer


Marketing authorisation holder



Bayer plc

Bayer Schering Pharma

Bayer House

Strawberry Hill

Newbury

Berkshire
RG14 1JA


Manufacturer: Bayer Schering Pharma AG




This medicinal product is authorised in the Member States of the EEA under the following names:


Austria: Ciproxin

Belgium: Ciproxine

Bulgaria: Ciprobay

Cyprus: Ciproxin

Czech Republic: Ciprobay

Denmark: Ciproxin

Finland: Ciproxin

France: Ciflox; Uniflox

Germany: Ciprobay

Greece: Ciproxin

Hungary: Ciprobay

Iceland: Ciproxin

Ireland: Ciproxin

Italy: Ciproxin

Luxembourg: Ciproxine

Malta: Ciproxin

Netherlands: Ciproxin

Norway: Ciproxin

Poland: Ciprobay

Portugal: Ciproxina

Slovenia: Ciprobay

Spain: Baycip

Sweden: Ciproxin

United Kingdom: Ciproxin




This leaflet was last approved in April 2010.



Advice/medical education


Antibiotics are used to cure bacterial infections. They are ineffective against viral infections.


If your doctor has prescribed antibiotics, you need them precisely for your current illness.


Despite antibiotics, some bacteria may survive or grow. This phenomenon is called resistance: some antibiotic treatments become ineffective.


Misuse of antibiotics increases resistance. You may even help bacteria become resistant and therefore delay your cure or decrease antibiotic efficacy if you do not respect appropriate:


  • dosages

  • schedules

  • duration of treatment


Consequently, to preserve the efficacy of this drug:


  • 1 - Use antibiotics only when prescribed.

  • 2 - Strictly follow the prescription.

  • 3 - Do not re-use an antibiotic without medical prescription, even if you want to treat a similar illness.

  • 4 - Never give your antibiotic to another person; maybe it is not adapted to her/his illness.

  • 5 - After completion of treatment, return all unused drugs to your chemist’s shop to ensure they will be disposed of correctly.

Friday, 17 August 2012

CHLORHEXIDINE GLUCONATE ANTISEPTIC MOUTHWASH PEPPERMINT FLAVOUR 0.2% W / V OROMUCOSAL SOLUTION





1. Name Of The Medicinal Product



CHLORHEXIDINE GLUCONATE ANTISEPTIC MOUTHWASH PEPPERMINT FLAVOUR 0.2% W/V OROMUCOSAL SOLUTION


2. Qualitative And Quantitative Composition



Chlorhexidine Gluconate 0.2% w/v



Excipients:



Macrogol glycerol hydroxystearate 0.7 % w/w



For full list of excipients see Section 6.1



3. Pharmaceutical Form



Oromucosal Solution.



A clear colourless solution.



4. Clinical Particulars



4.1 Therapeutic Indications



Chlorhexidine Gluconate Antiseptic Mouthwash is an antimicrobial solution which inhibits the formation of dental plaque. It is indicated as an aid to the treatment and prevention of gingivitis and in the maintenance of oral hygiene, particularly in situations where toothbrushing cannot be adequately employed (eg following oral surgery or in physically handicapped patients). It is used to promote gingival healing following periodontal surgery, to manage recurrent oral ulceration. Additionally it is useful in the treatment of denture stomatitis and thrush.



4.2 Posology And Method Of Administration

Children, adults and the elderly.


Chlorhexidine Gluconate Antiseptic Mouthwash should be used as required up to twice daily.



Rinse the mouth thoroughly for about 1 minute with 10 ml. Prior to dental surgery, the patient should be instructed to rinse the mouth with 10 ml for 1 minute. In the treatment of gingivitis a course of about one month is recommended (ie two bottles). For denture stomatitis cleanse and soak the denture in solution for 15 minutes twice daily. In the case of aphthous ulceration and oral candidal infections, treatment should be continued for 48 hours after clinical resolution.



4.3 Contraindications



Known hypersensitivity to any of the ingredients.



4.4 Special Warnings And Precautions For Use



For oral use only. Keep away from the eyes and ears. If solution comes into contact with the eyes, wash out well with water. Keep out of the reach and sight of children.



Macrogol glycerol hydroxystearate may cause skin reactions.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Chlorhexidine Gluconate 0.2% is incompatible with anionic agents which are usually present in conventional dentifrices. These should therefore be used before Chlorhexidine Gluconate Antiseptic Mouthwash (rinsing the mouth between applications) or at a different time of the day.



4.6 Pregnancy And Lactation



Chlorhexidine has been in widespread use for many years and no harmful effects in human pregnancy have been reported. However as with all drugs, caution should be exercised. Chlorhexidine Gluconate Antiseptic Mouthwash should be used only when the benefit to the mother has been assessed by a clinician.



4.7 Effects On Ability To Drive And Use Machines



None known.



4.8 Undesirable Effects



Irritative skin reactions to chlorhexidine can occur occasionally. Generalised allergic reactions to chlorhexidine have also been reported but are extremely rare.



A superficial discolouration of the dorsum of the tongue may occur. This disappears after treatment is discontinued. Discolouration of the teeth and silicate or composite restorations may also occur. This stain is not permanent and can largely be prevented by brushing with a conventional toothpaste daily before using the mouthwash. However, in certain cases, a professional prophylaxis (scaling and polishing) may be required to remove this stain completely. Stained anterior tooth-coloured restorations with poor margins or rough surfaces which are not adequately cleaned by professional prophylaxis may require replacement. Similarly where normal toothbrushing is not possible, as for example with intermaxillary fixation or with extensive orthodontic appliances, scaling and polishing may also be required once the underlying conditions have been resolved.



Transient disturbances of taste sensation and a burning sensation of the tongue may occur on initial use of the mouthwash. These effects usually diminish with continued use.



In cases where oral desquamation occurs it may be necessary to discontinue treatment. Very occasionally, swelling of the parotid glands during the use of oral chlorhexidine has been reported. In all cases spontaneous resolution has occurred on discontinuing treatment.


































System Organ Class




Very Common



(10%)




Common



(




Uncommon



(




Rare



(




Very Rare



(




Gastrointestinal Disorders



 

 


Tooth discolouration



Tongue discolouration



 


Oral mucosal exfoliation (desquamation)



Parotid gland enlargement




Immune System Disorders



 

 

 

 


Hypersensitivity




Nervous System Disorder



 


Dysgeusia (taste altered)



 

 

 


Skin and Subcutaneous Tissue Disorders



 

 

 


Skin irritation



 


4.9 Overdose



Chlorhexidine is poorly absorbed by the oral route, therefore systematic effects are unlikely even if large volumes are swallowed. However, gastric lavage followed by supportive measures may be used as appropriate.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Chlorhexidine gluconate is a bisguanide antiseptic and disinfectant which is bactericidal or bacteriostatic against a wide range of gram negative and gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophylic viruses. The antimicrobial activity covers most of the important species occurring in the oral microflora.



5.2 Pharmacokinetic Properties

Because of its cationic nature, chlorhexidine (gluconate) binds strongly to skin, mucosa and other tissues and is thus very poorly absorbed. No detectable blood levels have been found following oral use.


5.3 Preclinical Safety Data



Not applicable.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Chlorhexidine Gluconate Antiseptic Mouthwash contains the following inactive ingredients:



Ethanol



Sorbitol



Macrogol glycerol hydroxystearate



Peppermint Flavour: E1640 1 N1



Purified Water



6.2 Incompatibilities



Chlorhexidine Gluconate Antiseptic Mouthwash is incompatible with anionic agents which are often present in toothpastes. Therefore these should be used before the mouthwash, rinsing the mouth between applications, or at a different time of day.



Hypochlorite bleaches may cause brown stains to develop in fabrics previously in contact with chlorhexidine.



6.3 Shelf Life



Two years.



6.4 Special Precautions For Storage



Do not store above 25°C.



Store in the original container in order to protect from light



6.5 Nature And Contents Of Container



Amber PET bottle with a polypropylene screw cap. The cap is conical in shape and has “10 ml” and a level line engraved on the inside. The pack contains 300 ml.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Ecolab Ltd, Lotherton Way, Garforth, Leeds, LS25 2JY.



8. Marketing Authorisation Number(S)



PL 04509/0010



9. Date Of First Authorisation/Renewal Of The Authorisation



12th March 2008



10. Date Of Revision Of The Text



9th June 2011




Copaxone



Generic Name: Glatiramer Acetate
Class: Biologic Response Modifiers
Chemical Name: l-Glutamic acid polymer with l-alanine, l-lysine, and l-tyrosine, acetate
Molecular Formula: (C5H9NO4 • C3H7-5H9NO4 • C3H7NO2 • C6H14N2O2 • C9H11NO3)x • x(C2H4O2)
CAS Number: 147245-92-9

Introduction

Immunomodulatory agent; synthetic polypeptide mixture consisting of 4 naturally occurring amino acids.1 2 3 4 5 6 7 8


Uses for Copaxone


Multiple Sclerosis (MS)


Treatment to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS).1 6 7 8 9 16 18


The Medical Advisory Board of the National Multiple Sclerosis Society recommends therapy with an immunomodulator (e.g., glatiramer acetate, interferon-β) should be considered as soon as possible following a definite diagnosis of MS with a relapsing course and for selected patients with an initial attack who are at high risk for MS.14 15 18


May be useful in patients who do not respond adequately to or who do not tolerate interferon-β.15


Copaxone Dosage and Administration


Administration


Administer only by sub-Q injection; do not administer IV.1


Administer initial self-administered dose under the supervision of qualified clinicians.1


Sub-Q Administration


Commercially available prefilled syringes intended for single use only; discard unused portion.1


Warm prefilled syringes to room temperature by removing from refrigerator about 20 minutes prior to use.1 18


Inject sub-Q into the arm, abdomen, hip, or thigh.1 6 18


To minimize risk of serious injection site reactions (e.g., lipoatrophy, necrosis), rotate injection sites daily; follow a planned rotation of sites within an area so that any one area is not injected more than once every week.1 6 18 (See Acute Injection Reactions under Cautions.)


Dosage


Available as glatiramer acetate; dosage expressed in terms of the salt.a


Adults


Multiple Sclerosis

Sub-Q

20 mg once daily.1 6


Therapy should be continued indefinitely except when there is a clear lack of benefit, intolerable adverse effects, or availability of better treatments.14


Special Populations


No special population dosage recommendations at this time.1 6


Cautions for Copaxone


Contraindications



  • Known hypersensitivity to glatiramer, mannitol, or any other ingredient in the formulation.



Warnings/Precautions


Sensitivity Reactions


Hypersensitivity Reactions

Anaphylaxis accompanied by anti-glatiramer IgE antibodies reported rarely.10 18


General Precautions


Effects on Immune Response

Possible modification of immune response and interference with useful immune function.1


Possible interference with the recognition of foreign antigens, which may undermine the body’s tumor surveillance ability and defenses against infection.1


Possibility of adverse effects resulting from continued alteration of cellular immunity associated with chronic administration of the drug.1


Antibody Formation

Development of IgG antibodies to glatiramer reported in most patients;1 10 however, data to date indicate that antibodies do not neutralize therapeutic effects.3 18 20


Animal studies suggest that immune complexes are deposited in renal glomeruli.1


Acute Injection Reactions

Acute injection reactions reported in approximately 10% of patients, generally within minutes after sub-Q injection.a Symptoms are transient and generally self-limited and include flushing,1 2 6 7 8 chest pain1 2 6 or tightness,6 7 8 palpitations,1 2 5 6 7 8 anxiety,1 2 5 6 7 8 dyspnea,1 2 5 6 7 8 constriction of the throat,1 and urticaria.1


Reactions generally occur several months after initiation of therapy and generally are isolated events.7


Not currently known whether reactions have an immunologic or nonimmunologic mechanism.1 6


Chest Pain

Transient chest pain reported, generally >1 month after initiation of therapy.1 Episodes generally last only a few minutes, often are unassociated with other symptoms, and do not appear to produce clinically important sequelae.1


Injection Site Reactions

Injection site reactions, including lipoatrophy and, rarely, skin necrosis reported; injection site rotation and proper administration techniques may prevent these effects.a


Specific Populations


Pregnancy

Category B.1


Lactation

Not known whether glatiramer is distributed into milk.1 Use with caution in nursing women.1


Pediatric Use

Safety and efficacy not established in children <18 years of age.1


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1


Common Adverse Effects


Injection site reactions,1 2 5 vasodilation,1 chest pain,1 asthenia,1 infection,1 pain,1 nausea,1 arthralgia,1 anxiety,1 hypertonia.1


Interactions for Copaxone


Interactions with other drugs not fully evaluated to date.1


No clinically important interactions reported in clinical trials between glatiramer and drugs commonly used in multiple sclerosis, including concurrent corticosteroid therapy for up to 28 days.1 Not formally evaluated in combination with interferon-β.1 6


Copaxone Pharmacokinetics


Distribution


Following sub-Q injection, some portion of the dose may enter the lymphatic circulation and some may enter systemic circulation.1 Does not appear to cross the blood-brain barrier.6


Elimination


Metabolism


Hydrolyzed locally at injection site to small oligopeptides and free amino acids.1 6


Stability


Storage


Parenteral


Injection

2–8°C; protect from light.a May be stored at room temperature (15–30°C) for up to one week.1


ActionsActions



  • Mechanism of action not fully elucidated;1 appears to modify immune processes responsible for the pathogenesis of MS.1 6 8 15




  • Induces and activates drug-specific suppressor T-cells that migrate into the CNS and down-regulate immune response (e.g., inflammation) to myelin antigens in the periphery.1 6 8 15



Advice to Patients



  • Importance of reading and understanding manufacturer’s patient information before beginning therapy.1




  • Importance of clinicians instructing patient and/or caregivers in proper injection techniques and about avoiding reuse of syringes and needles and proper disposal of such equipment in a puncture-resistant container after use.1




  • Importance of clinicians advising patient about adverse effects, including instructions to contact clinician immediately and withhold further administration of the drug if hives, skin rash with irritation, dizziness, sweating, chest pain, breathing difficulty, or severe pain at the injection site occurs.1




  • Importance of not changing dosage or discontinuing therapy without consulting clinician.1




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of patient informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1




  • Importance of informing patients of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.













Glatiramer Acetate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Parenteral



Injection, for subcutaneous use



20 mg/1 mL



Copaxone (available as 1-mL prefilled syringe)



TEVA Neuroscience



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions June 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. TEVA Neuroscience. Copaxone (glatiramer acetate injection) prescribing information. Kansas City, MO; 2004 Feb.



2. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995; 45:1268-76. [IDIS 350103] [PubMed 7617181]



3. Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998; 50:701-8. [IDIS 403141] [PubMed 9521260]



4. Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987; 317:408-14. [IDIS 232708] [PubMed 3302705]



5. Comi G, Filippi M, Wolinsky JS et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001; 49:290-7. [IDIS 461166] [PubMed 11261502]



6. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002; 16:825-50. [PubMed 12421116]



7. Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology. 2002; 58(Suppl 4):S10-S22.



8. Miller AE. Glatiramer acetate in the treatment of multiple sclerosis. Neurol Clin. 2005; 23:215-31. [PubMed 15661095]



9. Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS council for clinical practice guidelines. Neurology. 2002; 58: 169-178. [IDIS 475332] [PubMed 11805241]



10. Rauschka H, Farina C, Sator P et al. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology. 2005; 64:1481. [IDIS 534043] [PubMed 15851756]



11. Ge Y, Grossman RI, Udupa JK et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Neurology. 2000; 54:813-7. [IDIS 443731] [PubMed 10690968]



12. Johnson KP, Ford CC, LIsak RP et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand. 2005; 111:42-7. [PubMed 15595937]



13. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology. 2004; 63(Suppl 6):S8-S14. [IDIS 528071] [PubMed 15623672]



14. Disease management consensus statement from the Medical Advisory Board of the National Multiple Sclerosis Society. Available at: http://www.nationalmssociety.org/pdf/forpros/Exp_Consensus.pdf. Accessed September 6, 2005.



15. Mezzapesa DM, Rovaris M, Filippi M. Glatiramer acetate in multiple sclerosis. Expert Rev Neurotherapeutics. 2005; 5:451-8.



16. Boneschi FM, Rovaris M, Johnson KP et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis. 2003; 9:349-55. [PubMed 12926839]



17. Johnson KP, Brooks BR, Ford CC et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Multiple Sclerosis. 2003; 9:585-91. [PubMed 14664471]



18. Teva Neuroscience, Overland Park, KS. Personal communication.



19. Johnson KP, Panitch HS, Ford CC et al. Long-term slowing of disability progression in patients receiving continuous glatiramer acetate compared with those withdrawing from therapy: 10 year results from an ongoing trial. Neurology. 2004; 62(7 Suppl 5):A180.



20. Teitelbaum D, Brenner T, Abramsky O et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler. 2003; 9:592-9. [PubMed 14664472]



a. TEVA Neuroscience. Copaxone (glatiramer acetate injection) prescribing information. Kansas City, MO; 2006 May.



More Copaxone resources


  • Copaxone Side Effects (in more detail)
  • Copaxone Use in Pregnancy & Breastfeeding
  • Copaxone Drug Interactions
  • Copaxone Support Group
  • 29 Reviews for Copaxone - Add your own review/rating


  • Copaxone Prescribing Information (FDA)

  • Copaxone Advanced Consumer (Micromedex) - Includes Dosage Information

  • Copaxone MedFacts Consumer Leaflet (Wolters Kluwer)

  • Copaxone Consumer Overview



Compare Copaxone with other medications


  • Multiple Sclerosis

Monday, 13 August 2012

Liquifilm Tears Preservative Free





1. Name Of The Medicinal Product



Liquifilm® Tears Preservative Free



or



Refresh OphthalmicTM


2. Qualitative And Quantitative Composition



Polyvinyl alcohol 1.4% w/v.



3. Pharmaceutical Form



Eye drops, solution



4. Clinical Particulars



4.1 Therapeutic Indications



Symptomatic relief of dry eye and symptomatic relief of eye irritation associated with deficient tear production.



4.2 Posology And Method Of Administration



Ensure container is intact. Twist off tab and apply eyedrops.



Dosage schedule: Apply one or two drops in each eye as needed, or as directed. No special dosage for the elderly or for children.



Route of administration: Ocular instillation.



4.3 Contraindications



Hypersensitivity to the active substance polyvinyl alcohol or any of the other excipients.



4.4 Special Warnings And Precautions For Use



If irritation, pain, redness and changes in vision occur or worsen, treatment should be discontinued and a new assessment considered.



To avoid contamination, the dropper tip should not be allowed to touch the eye or any other surface.



Contact lenses should be removed before each application and may be reinserted after 15 minutes.



Concomitant ocular medication should be administered 15 minutes prior to the instillation of Liquifilm Tears Preservative Free or Refresh Ophthalmic.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No interaction studies have been performed.



4.6 Pregnancy And Lactation



The constituents of Liquifilm Tears Preservative Free or Refresh Ophthalmic have been used as pharmaceutical agents for many years with no untoward effects. No special precautions are necessary for the use of Liquifilm Tears Preservative Free or Refresh Ophthalmic in pregnancy and lactation.



4.7 Effects On Ability To Drive And Use Machines



Liquifilm Tears Preservative Free or Refresh Ophthalmic has minor or moderate influence on the ability to drive and use machines as it may cause transient blurring of vision. Do not drive or use hazardous machinery unless vision is clear.



4.8 Undesirable Effects



Liquifilm Tears Preservative Free or Refresh Ophthalmic may cause transient stinging or irritation on instillation.



The frequency of the following undesirable effects is not known (cannot be estimated from the available data).



Eye disorders



• Eye irritation



• Eye pain



• Ocular hyperaemia



• Vision blurred



• Eye pruritus



• Foreign body sensation



• Eye discharge



• Hypersensitivity



4.9 Overdose



No case of overdose has been reported. Accidental overdose will not present any hazard.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Liquifilm® Tears Preservative Free / or Refresh OphthalmicTM exerts a mechanical, not a pharmacological action. The viscosity enhancing agent is polyvinyl alcohol and the lubricating-enhancing agent is povidone.



5.2 Pharmacokinetic Properties



Not applicable



5.3 Preclinical Safety Data



The constituents of Liquifilm® Tears Preservative Free / or Refresh OphthalmicTM have been used safely in pharmaceutical products for many years. Topical administration in animals studies showed no untoward effects.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Povidone



Sodium chloride



Sodium hydroxide or hydrochloric acid (to adjust pH)



Purified water



6.2 Incompatibilities



None known.



6.3 Shelf Life



24 months (unopened).



Do not store opened container.



6.4 Special Precautions For Storage



Store at 25ºC or below.



6.5 Nature And Contents Of Container



Low density polyethylene unit dose vials containing 0.4 ml of Liquifilm® Tears Preservative Free / or Refresh OphthalmicTM.



Cartons contain 2, 5, 10, 15, 30 or 50 units per pack.



6.6 Special Precautions For Disposal And Other Handling



Ensure container is intact. Twist off tab and apply eyedrops.



7. Marketing Authorisation Holder



Allergan Limited



Marlow International



The Parkway



Marlow



Bucks, SL7 1YL



UK



8. Marketing Authorisation Number(S)



PL 00426/0063



9. Date Of First Authorisation/Renewal Of The Authorisation



14th August 2003



10. Date Of Revision Of The Text



23rd July 2008